ReviewJACC. Basic to translational science2025
The Cardiohepatic Axis in Heart Failure.
Review in JACC. Basic to translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Association between albumin-bilirubin (ALBI) score and all-cause mortality in critically ill patients with pulmonary embolism: a cohort study based on the MIMIC-IV database.Journal of thoracic disease · 2026Article
- Metabolic reprogramming in fibrosis-related diseases: underlying mechanisms and therapeutics.Molecular biomedicine · 2026Review
- Immunometabolic Organ Crosstalk in Heart Failure with Preserved Ejection Fraction: The Role of Dietary Patterns in Obesity-Related Inflammation.Nutrients · 2026Review
- Bidirectional association between non-steatotic chronic liver disease and heart disease: the potential link of insulin resistance.Cardiovascular diabetology · 2026Article
- Liver Function Abnormalities in Acute Heart Failure: A State-of-the-art Review from an International Expert Group.Cardiac failure review · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiogenic liver disease is a sequela of hepatic congestion from right heart failure that leads to hepatic dysfunction and adverse liver remodeling. Understanding the mechanisms and consequences of liver pathology in the syndrome of heart failure is an important unmet need in the care of patients with chronic heart failure. Liver congestion provokes profound responses in hepatocytes and nonparenchymal cells including endothelial cells, macrophages, and hepatic stellate cells. However, the pathways that drive liver fibrosis and dysfunction are poorly understood. Recent human and preclinical data has begun to unravel the cellular landscape and molecular pathways that define cardiogenic liver disease. This review aims to discuss our current understanding of the cardiohepatic axis in heart failure while also highlighting knowledge gaps and opportunities for future investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.